MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation
MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation
复制标题
DOI：
10.1111/j.1399-0004.2007.00955.x
复制
发表时间：
2008-03-01
影响因子：
3.5
通讯作者：
Zheng, S. S.
中科院分区：
文献类型：
--
作者：
Wu, L. M.;Zhang, F.;Zheng, S. S.
基质金属蛋白酶（MMP）基因的遗传变异可能影响这些酶的生物学功能，改变它们在肿瘤发生发展中的作用。MMP 2 C-1306 T和MMP 9 C-1562 T多态性对各种癌症遗传易感性的影响已被研究。然而，这些多态性和肝细胞癌（HCC）肝移植（LT）后复发的风险之间的关系还没有报道。本研究旨在调查这两个位点与93例接受LT治疗的HCC患者的HCC复发风险的相关性。采用直接DNA测序进行基因分型。对于MMP 2 C-1306 T变异，CT杂合子患者的复发风险降低58%（风险比：0.419; 95%置信区间：0.177-0.994）。CT基因型患者的平均无复发生存期明显长于纯合子CC患者（30.4 vs 19.3个月，p = 0.019）。然而，MMP 9 C-1562 T多态性与HCC复发之间没有发现关联（p = 0.259）。这些发现表明MMP 2启动子多态性可能对肝细胞癌LT后复发有一定的预测价值。
Genetic variants in matrix metalloproteinase (MMP) gene may influence the biological function of these enzymes and change their role in carcinogenesis and progression. The effect of MMP2 C-1306T and MMP9 C-1562T polymorphisms on genetic susceptibility has been investigated in various kinds of cancer. However, the relationship between these polymorphisms and risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has not been reported. The present study was designed to investigate the association of these two loci with the risk of HCC recurrence in 93 HCC patients treated with LT. Genotyping was performed using direct DNA sequencing. For MMP2 C-1306T variant, patients with CT heterozygous conferred a 58% reduction in recurrence risk (risk ratio: 0.419; 95% confidence interval: 0.177-0.994). The mean recurrence-free survival for CT genotype was significantly longer than that for homozygous CC patients (30.4 vs 19.3 months, p = 0.019). However, no association was found between MMP9 C-1562T polymorphisms and recurrence of HCC (p = 0.259). These findings suggest that MMP2 promoter polymorphisms may provide some predictive value for HCC recurrence after LT.